Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason A Dubovsky

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2009
Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigenJason A Dubovsky, Douglas G McNeel, John J Powers, et al.
Blood|September 27, 2014
IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cellsShuai Dong, Daphne Guinn, Jason A Dubovsky, et al.
Leukemia & Lymphoma|January 29, 2011
A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitorsJohn J Powers, Jason A Dubovsky, P K Epling-Burnette, et al.
Leukemia Research|September 25, 2010
Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiersJason A Dubovsky, Daniel Wang, John J Powers, et al.
Blood Advances|April 20, 2018
Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphomaAnita Kumar, Santosha Vardhana, Alison J Moskowitz, et al.
Blood|September 7, 2013
Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homingJason A Dubovsky, Danielle L Chappell, Bonnie K Harrington, et al.
The Journal of Biological Chemistry|January 17, 2015
Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694Yiming Zhong, Shuai Dong, Ethan Strattan, et al.
Blood|May 15, 2015
Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activationTa-Ming Liu, Jennifer A Woyach, Yiming Zhong, et al.
Journal of Proteomics|January 18, 2016
Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markersSean W Harshman, Alessandro Canella, Paul D Ciarlariello, et al.
Blood|December 7, 2013
Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)Jennifer A Woyach, Engin Bojnik, Amy S Ruppert, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2009
Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigenJason A Dubovsky, Douglas G McNeel, John J Powers, et al.
Blood|September 27, 2014
IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cellsShuai Dong, Daphne Guinn, Jason A Dubovsky, et al.
Leukemia & Lymphoma|January 29, 2011
A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitorsJohn J Powers, Jason A Dubovsky, P K Epling-Burnette, et al.
Leukemia Research|September 25, 2010
Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiersJason A Dubovsky, Daniel Wang, John J Powers, et al.
Blood Advances|April 20, 2018
Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphomaAnita Kumar, Santosha Vardhana, Alison J Moskowitz, et al.
Blood|September 7, 2013
Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homingJason A Dubovsky, Danielle L Chappell, Bonnie K Harrington, et al.
The Journal of Biological Chemistry|January 17, 2015
Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694Yiming Zhong, Shuai Dong, Ethan Strattan, et al.
Blood|May 15, 2015
Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activationTa-Ming Liu, Jennifer A Woyach, Yiming Zhong, et al.
Journal of Proteomics|January 18, 2016
Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markersSean W Harshman, Alessandro Canella, Paul D Ciarlariello, et al.
Blood|December 7, 2013
Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)Jennifer A Woyach, Engin Bojnik, Amy S Ruppert, et al.
Pageof 3